GT
GTG.AU Genetic Technologies Ltd
- Market cap
- AUD 5.67M
- P/E
- -
- P/B
- 1.95x
- ROE
- -14,633.1%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the fiscal year ending Jun 2025.
Is GTG.AU undervalued?
Graham numberThe Graham number of Genetic Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genetic Technologies Ltd fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-14,633.1%), below 10%.
ROA 0/1
Return on assets (-14,633.1%) is below the industry median (-36.5%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Earnings growth cannot be compared with the industry.
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.9x) is below the industry median (3.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genetic Technologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company a…
Full company profileGenetic Technologies Ltd financial statements
Genetic Technologies Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 825K | 519K | 189K | 25.4K | 9.86K | 121K | 6.79M | 10.3M | 7.66M | 0.00 |
| Gross Profit | 81.5K | 26.1K | -111K | -251K | -242K | -240K | 6.47M | 6.01M | 3.90M | -204K |
| Operating Income | -8.49M | -8.17M | -6.40M | -6.00M | -6.08M | -7.42M | -7.54M | -10.4M | -12.2M | -2.78M |
| EBITDA | -8.10M | -7.80M | -5.46M | -6.86M | -6.02M | -6.58M | -7.20M | -11.2M | -11.4M | -315K |
| Net Income | -8.46M | -8.40M | -5.46M | -6.83M | -6.10M | -7.08M | -7.13M | -11.8M | -12.0M | -1.46M |
| EPS | -0.49 | -0.40 | -0.22 | -0.24 | -0.15 | -0.08 | -0.08 | -0.12 | -0.09 | - |
| Balance Sheet | ||||||||||
| Total Assets | 13.3M | 12.1M | 6.17M | 3.27M | 15.6M | 23.0M | 20.8M | 14.9M | 6.19M | 10.0K |
| Total Liabilities | 1.41M | 1.53M | 1.45M | 1.49M | 1.64M | 1.44M | 4.37M | 3.69M | 4.36M | 0.00 |
| Shareholders' Equity | 11.9M | 10.6M | 4.71M | 1.77M | 14.0M | 21.5M | 16.4M | 11.2M | 1.83M | 10.0K |
| Cash & Short-term Investments | 11.2M | 11.0M | 5.49M | 2.19M | 14.2M | 20.9M | 11.7M | 7.87M | 1.02M | 10.0K |
| Total Debt | - | - | - | 482K | 482K | 204K | 653K | 533K | 875K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.73M | -6.81M | -5.64M | -6.07M | -5.71M | -6.30M | -5.66M | -9.72M | -9.68M | - |
| Capital Expenditure | 303K | 235K | 2.39K | 50.3K | 38.1K | 642K | 96.8K | 17.6K | 33.0K | 7.08K |
| Free Cash Flow | -8.03M | -7.05M | -5.64M | -6.12M | -5.75M | -6.94M | -5.76M | -9.74M | -9.71M | -1.36M |
| Ratios | ||||||||||
| ROE | -71.2% | -79.4% | -116.0% | -385.8% | -43.6% | -32.9% | -43.4% | -105.3% | -656.5% | -14,633.1% |
| ROA | -63.7% | -69.4% | -88.6% | -209.3% | -39.0% | -30.8% | -34.3% | -79.1% | -194.2% | -14,633.1% |
| Net Profit Margin | -1,025.8% | -1,620.8% | -2,887.1% | -26,855.4% | -61,830.2% | -5,870.9% | -104.9% | -113.6% | -156.8% | - |
| Debt to Equity | - | - | - | 0.27x | 0.03x | 0.01x | 0.04x | 0.05x | 0.48x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genetic Technologies Ltd dividends
Genetic Technologies Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:100 on Dec 14, 2023.
Who owns Genetic Technologies Ltd
- Insiders 89.56%
- Institutions 0.00%
- Public & others 10.44%
- Shares outstanding 145M
- Free float 162M
Genetic Technologies Ltd company profile
- Company name
- Genetic Technologies Ltd
- Ticker
- GTG.AU
- ISIN
- AU000000GTG7
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 55
- Fiscal year end
- June
- Address
- T1 404 Kon-Tiki Business Centre, Maroochydore, QLD, Australia, 4558
- Phone
- 61 3 0087 6693
- Website
- genetype.com
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Maroochydore, Australia.
Genetic Technologies Ltd management
5- Mr. Michael WalkerExecutive Chairman & MD
- Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultant · born 1963
- Mr. Kevin CamilleriChief Executive Officer of EasyDNA · born 1978
- Ms. Priyamvada Sanjay RasalCompany Secretary
- Dr. Erika Spaeth Ph.D.Director of Clinical & Scientific Affairs